Jeffrey Weber, MD, PhD
Adjuvant therapy has revolutionized the field of melanoma by treating patients with resected disease with active regimens that have historically been used in the metastatic setting, said Jeffrey S. Weber, MD, PhD.
In 2014, the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) was granted accelerated approval for use in patients with unresectable or metastatic melanoma who harbor a BRAF
mutation. Subsequently, the combination was evaluated as an adjuvant therapy in the phase III COMBI-AD trial in patients with resected stage III, BRAF
... to read the full story